Trial Profile
A pilot study of the efficacy and safety of BMS-512148 [dapaglifozin] on glycaemic control in subjects with type 2 diabetes treated aggressively but not controlled on combination antihyperglycaemic therapy with metformin and/or thiazolidinedione (TZD) and insulin
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 01 Nov 2016 Results of a pooled post-hoc analysis of five phase IIb and 16 phase III studies (including this study) assessing frequency and characteristics of hypersensitivity adverse events, published in the Clinical Drug Investigation.
- 16 Sep 2016 Results of a pooled analysis from this and 13 other trials, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 18 Sep 2014 Results of a pooled analysis of 13 phase IIb/III trials were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.